SCHEMBL4474546

SCHEMBL4474546

COc1cc2c(Oc3ccc(NC(=O)NCCC(C)(C)C)c(F)c3)ccnc2cc1OCCNCCO

nearest known ligand 0.68

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 5/20 0.68
KDR P35968 9/20 0.61
PDGFRA P16234 9/20 0.61
AXL P30530 6/20 0.61
KIT P10721 3/20 0.61
PDGFRB P09619 1/20 0.58
MET P08581 3/20 0.49
EGFR P00533 1/20 0.49
RET P07949 1/20 0.49
IGF1R P08069 1/20 0.49
SRC P12931 1/20 0.49
MST1R Q04912 1/20 0.49
HDAC1 Q13547 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4468211 0.98 FGFR2 (0.65) FGFR2KDRPDGFRAAXLKIT
SCHEMBL4465227 0.91 PDGFRA (0.72) FGFR2KDRPDGFRAAXLKIT
SCHEMBL4466896 0.91 FGFR2 (0.58) FGFR2KDRPDGFRAAXLKIT
SCHEMBL13955472 0.91 KDR (0.65) FGFR2KDRPDGFRAAXLKIT
Hydrochloric Acid SCHEMBL5097587 0.91 PDGFRA (0.71) FGFR2KDRPDGFRAAXLKIT
SCHEMBL4482090 0.90 KDR (0.64) FGFR2KDRPDGFRAAXLKIT
SCHEMBL4478550 0.90 KDR (0.64) FGFR2KDRPDGFRAAXLKIT
SCHEMBL4469958 0.89 KDR (0.59) FGFR2KDRPDGFRAAXLKIT
SCHEMBL4473702 0.89 KDR (0.56) FGFR2KDRPDGFRAAXLKIT
SCHEMBL4467319 0.88 KDR (0.58) FGFR2KDRPDGFRAAXLKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 FGFR2 2/4885KDR 211/4885PDGFRA 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.